KR-HT5 is based on Akoya’s PhenoImager® HT PlatformMARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences,...
MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the...
LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United Kingdom, May 02, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading...
Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP;...
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in...
Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ETNEW YORK, May 02, 2024 (GLOBE NEWSWIRE)...
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it...
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June...
Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend...
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)...
LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important yearJANUARY - MARCH...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court...
The new firm promises to bring a new model for a consulting partner in the life sciences industry. NEW YORK,...
New Appointments Underscore Commitment to Driving Innovation and Industry-Leading GrowthLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer,...
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from...
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and...
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or...
Significant POLB 001 Patent Granted in United StatesImmunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON,...
$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the...